MSR63 Cost-Effectiveness Modeling Based on a Clinical Trial Re-analysis Using Multimodal Machine Artificial Intelligence Methodology: Predicting Which Patients May Benefit Most From the Addition of Tremelimumab to Durvalumab Plus Chemothera ...
Abstract
Authors
Tristan Gonzalez Amanda Remorino Miguel Miranda Vivian Peirce David Heidenwag Colin Thierry Rucha Vadia